Spots Global Cancer Trial Database for Novel MRE Technique to Assess a Risk Factor for Liver Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Novel MRE Technique to Assess a Risk Factor for Liver Cancer

Official Title: Novel MRE Technique to Assess Tissue Viscoelasticity as a Risk Factor for Liver Cancer

Study ID: NCT05165446

Conditions

NASH - Nonalcoholic Steatohepatitis

Interventions

Study Description

Brief Summary: The aim of this proposal is to investigate a novel imaging method to identify patients with non-alcoholic steatohepatitis (NASH) who are at risk for hepatocellular carcinoma (HCC).

Detailed Description: NASH is the most common cause of chronic liver disease, and it is estimated that 40-50% of patients with obesity and T2DM have NASH. NASH can lead to HCC with the risk increasing 2-3 fold in patient with poor glycemic control. Unless caught early, HCC has a poor prognosis with no effective therapies. A unique feature of HCC in NASH is that it often arises at a pre-cirrhotic stage, and the prognosis is often dismal. There are no current surveillance strategies for these pre-cirrhotic patients. Based on our animal models and pilot patient studies, we developed a novel paradigm that linked liver matrix changes to a more aggressive HCC phenotype. Our goal is to develop an imaging-based surveillance tool that will identify early matrix changes that may predispose to HCC.